First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $33.96M fell 18.1% year over year.
Context
- Research & development increased in 1 of the last 2 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 139.61M USD
- Year-over-year change
- -8.4%
- 2-year CAGR
- +19.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 139.61M | -8.4% |
| FY2024 | 2024-12-31 | 152.35M | +56.1% |
| FY2023 | 2023-12-31 | 97.59M | — |
Research & Development vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's FY2025 research & development of $139.61M is the 3rd highest of the 10 companies compared; the peer median is $69.93M.
- Its year-over-year change of -8.4% is the 8th highest of 10, against a peer median of +20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M | +59.9% | — | 4011.3% | |
| LTM Jun 2026 | $49.22M | +63.5% | -1.9% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $38.72M | -52.9% | +21.2% | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $69.93M | +20.4% | +18.2% | 2344.6% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 152.35M | 139.61M |
| Gross Profit | 0 | (152.35M) | (139.61M) |
| Gross Margin | — | — | — |
| Research & Development | 97.59M | 152.35M | 139.61M |
| Selling, General & Admin | 20.87M | 28.76M | 39.39M |
| Operating Expenses | 118.46M | 28.76M | 39.39M |
| Depreciation & Amortization | 2.38M | 2.4M | 559K |
| EBITDA | (116.09M) | (178.7M) | (178.45M) |
| EBITDA Margin | — | — | — |
| Operating Income | (118.46M) | (181.1M) | (179.01M) |
| Operating Margin | — | — | — |
| Interest Income | 12.31M | 17.38M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 12.31M | 17.4M | 12.92M |
| Income Before Tax | (106.15M) | (163.71M) | (166.09M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Net Margin | — | — | — |
| EPS (Basic) | (3.05) | 0.00 | 0.00 |
| EPS (Diluted) | (3.05) | 0.00 | 0.00 |
| Weighted Avg Shares | 34.75M | 0 | 0 |
| Weighted Avg Shares (Diluted) | 34.75M | 0 | 0 |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.